45 patents
Utility
Shiga toxin A subunit effector polypeptides, Shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
2 Jan 24
The present invention provides Shiga toxin A Subunit derived polypeptides, scaffolds, and cell-targeting molecules comprising amino acid substitutions which equip the molecules with site-specific positions (and often unique amino acid residues in the molecule) for linking other molecules while retaining Shiga toxin function(s), such as, e.g., efficient intracellular routing and/or potent cytotoxicity.
Eric Poma, Erin Willert
Filed: 23 Nov 21
Utility
CTLA-4 Binding Molecules Comprising Shiga Toxin a Subunit Scaffolds and Uses Thereof
9 Nov 23
Provided herein are binding molecules that each comprise (1) a Shiga toxin A subunit effector polypeptide and (2) a binding region capable of specifically binding CTLA-4 on the surface of cell, such as a tumor cell or an immunosuppressive immune cell.
Eric POMA, Erin WILLERT, Aimee IBERG, Swati KHANNA, Roger WALTZMAN, Kogan BAO
Filed: 8 Mar 23
Utility
HER2-TARGETING Molecules Comprising De-immunized, Shiga Toxin a Subunit Scaffolds
19 Oct 23
Provided herein are HER2-targeting molecules comprising Shiga toxin A Subunit derived polypeptides having 1) de-immunization and 2) reduced, protease-cleavage sensitivity while retaining Shiga toxin function(s), such as, e.g., potent cytotoxicity via ribosome inhibition.
Eric POMA, Erin WILLERT, Jack HIGGINS
Filed: 16 Feb 23
Utility
Clinical Methods for Use of HER2 Binding Molecules
21 Sep 23
Provided herein are methods for treating or preventing cancer comprising administering to a subject in need thereof an effective amount of a HER2 binding molecule comprising a cytotoxic Shiga toxin A subunit effector polypeptide and a binding region capable of specifically binding an extracellular part of human HER2.
Eric POMA, Roger WALTZMAN, Jack HIGGINS, Eric WILLIAMS
Filed: 22 Jul 21
Utility
CD38-binding proteins comprising de-immunized Shiga toxin A subunit effectors
1 Aug 23
The instant invention provides binding proteins (“CD38-binding proteins”) which each comprise (1) a CD38-binding region for cell-targeting and (2) a Shiga toxin A Subunit effector polypeptide (“Shiga toxin effector polypeptide”).
Nibedita Chattopadhyay, Eric Poma, Erin Willert
Filed: 23 Jan 20
Utility
Cell-targeting Molecules Comprising Shiga Toxin a Subunit Effectors and CD8+ T-cell Epitopes
22 Dec 22
The present invention provides cell-targeting molecules which can deliver a CD8+ T-cell epitope cargo to the MHC class I presentation pathway of the cell.
Eric Poma, Erin Willert, Jason Kim
Filed: 27 Aug 21
Utility
Cell-targeting Molecules Comprising De-immunized, Shiga Toxin a Subunit Effectors and CD8+ T-cell Epitopes
10 Nov 22
The present invention provides cell-targeting molecules which can deliver a CD8+ T-cell epitope cargo to the MHC class I presentation pathway of a target cell.
Eric POMA, Erin WILLERT, Sangeetha RAJAGOPALAN, Garrett Lee ROBINSON, Brigitte BRIESCHKE, Jason KIM
Filed: 29 Jun 22
Utility
PD-L1 Binding Proteins Comprising Shiga Toxin a Subunit Scaffolds and CD8+ T Cell Antigens
29 Sep 22
Provided herein are PD-L1 binding molecules comprising a toxin, e.g. a Shiga toxin A Subunit derived polypeptide.
Eric Poma, Hilario Ramos, Erin Willert, Joseph Dekker, Swati Khanna
Filed: 17 Mar 22
Utility
MHC Class I Epitope Delivering Polypeptides
29 Sep 22
The present invention is directed to T-cell epitope delivering polypeptides which deliver one or more CD8+ T-cell epitopes to the MHC class I presentation pathway of a cell, including toxin-derived polypeptides which comprise embedded T-cell epitopes and are de-immunized.
Eric POMA, Erin WILLERT
Filed: 28 Mar 22
Utility
De-immunized, Shiga Toxin a Subunit Scaffolds and Cell-targeting Molecules Comprising the Same
8 Sep 22
The present invention relates to Shiga toxin A Subunit derived polypeptides and cell-targeting molecules comprising amino acid substitutions which equip the polypeptides with 1) de-immunization; 2) reduced, protease-cleavage sensitivity; and/or 3) a heterologous epitope cargo(s) while retaining Shiga toxin function(s), such as, e.g., potent cytotoxicity.
Eric POMA, Erin WILLERT, Garrett Lee ROBINSON, Sangeetha RAJAGOPALAN, Brigitte BRIESCHKE
Filed: 17 May 22
Utility
De-immunized Shiga Toxin a Subunit Effector Polypeptides for Applications In Mammals
1 Sep 22
The present invention relates to Shiga toxin effector polypeptides with reduced antigenic and/or immunogenic potential.
Eric Poma, Erin Willert, Garrett Lee Robinson, Sangeetha Rajagopalan, Brigitte Brieschke
Filed: 11 Jun 21
Utility
Proteins Comprising Binding Regions, Shiga Toxin a Subunit Effector Regions, and Carboxy-terminal, Endoplasmic Reticulum Localization Signal Motifs
25 Aug 22
The present invention provides proteins comprising binding regions for cell-type specific targeting, Shiga toxin effector regions derived from A Subunits of members of the Shiga toxin family for providing Shiga toxin effector functions (e.g. cellular internalization and cytotoxicity), and carboxy-terminal endoplasmic reticulum localization signal motifs.
Eric POMA, Erin WILLERT, Jason KIM, Jack HIGGINS
Filed: 2 May 22
Utility
Cell-targeting molecules comprising de-immunized, Shiga toxin a subunit effectors and CD8+ t-cell epitopes
9 Aug 22
The present invention provides cell-targeting molecules which can deliver a CD8+ T-cell epitope cargo to the MHC class I presentation pathway of a target cell.
Eric Poma, Erin Willert, Sangeetha Rajagopalan, Garrett Lee Robinson, Brigitte Brieschke, Jason Kim
Filed: 12 Apr 21
Utility
Shiga toxin a subunit effector polypeptides, Shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
19 Jul 22
The present invention provides Shiga toxin A Subunit derived polypeptides, scaffolds, and cell-targeting molecules comprising amino acid substitutions which equip the molecules with site-specific positions (and often unique amino acid residues in the molecule) for linking other molecules while retaining Shiga toxin function(s), such as, e.g., efficient intracellular routing and/or potent cytotoxicity.
Eric Poma, Erin Willert
Filed: 7 May 21
Utility
Clinical Methods for Use of a PD-L1-BINDING Molecule Comprising a Shiga Toxin Effector
23 Jun 22
The present disclosure relates to PD-L1-binding molecules comprising a Shiga toxin effector region, a PD-L1-binding region, and a T cell epitope, and pharmaceutical compositions thereof.
Eric POMA, Erin WILLERT, Hilario RAMOS, Jensing LIU, Roger Waltzman
Filed: 16 Dec 21
Utility
De-immunized, Shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
21 Jun 22
The present invention relates to Shiga toxin A Subunit derived polypeptides and cell-targeting molecules comprising amino acid substitutions which equip the polypeptides with 1) de-immunization; 2) reduced, protease-cleavage sensitivity; and/or 3) a heterologous epitope cargo(s) while retaining Shiga toxin function(s), such as, e.g., potent cytotoxicity.
Eric Poma, Erin Willert, Garrett Lee Robinson, Sangeetha Rajagopalan, Brigitte Brieschke
Filed: 19 Apr 21
Utility
HER2-TARGETING Molecules Comprising De-immunized, Shiga Toxin a Subunit Scaffolds
26 May 22
Provided herein are HER2-targeting molecules comprising Shiga toxin A Subunit derived polypeptides having 1) de-immunization and 2) reduced, protease-cleavage sensitivity while retaining Shiga toxin function(s), such as, e.g., potent cytotoxicity via ribosome inhibition.
Eric POMA, Erin WILLERT, Jack HIGGINS
Filed: 6 Dec 21
Utility
MHC class I epitope delivering polypeptides
26 Apr 22
The present invention is directed to T-cell epitope delivering polypeptides which deliver one or more CD8+ T-cell epitopes to the MHC class I presentation pathway of a cell, including toxin-derived polypeptides which comprise embedded T-cell epitopes and are de-immunized.
Eric Poma, Erin Willert
Filed: 15 Apr 21
Utility
Multivalent CD20-binding molecule comprising Shiga toxin A subunit effector polypeptides and enriched compositions thereof
15 Feb 22
Provided herein are multivalent CD20-binding molecules, and compositions thereof, for use in selective killing of specific cell types and/or as therapeutics for the treatment of a variety of diseases, including cancer, tumors, and immune disorders.
Eric Poma, Erin Willert, Jason Kim, Jack Higgins, Jensing Liu, Rodney Flores-Lefranc
Filed: 11 Oct 16
Utility
HER2-targeting molecules comprising de-immunized, Shiga toxin A subunit scaffolds
18 Jan 22
Provided herein are HER2-targeting molecules comprising Shiga toxin A Subunit derived polypeptides having 1) de-immunization and 2) reduced, protease-cleavage sensitivity while retaining Shiga toxin function(s), such as, e.g., potent cytotoxicity via ribosome inhibition.
Eric Poma, Erin Willert, Jack Higgins
Filed: 16 Oct 20